SG11201707497UA - Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease - Google Patents

Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Info

Publication number
SG11201707497UA
SG11201707497UA SG11201707497UA SG11201707497UA SG11201707497UA SG 11201707497U A SG11201707497U A SG 11201707497UA SG 11201707497U A SG11201707497U A SG 11201707497UA SG 11201707497U A SG11201707497U A SG 11201707497UA SG 11201707497U A SG11201707497U A SG 11201707497UA
Authority
SG
Singapore
Prior art keywords
etc1002
ezetimibe
formulations
risk
treating
Prior art date
Application number
SG11201707497UA
Inventor
Roger Schofield Newton
Noah Laban Rosenberg
Diane Elaine Macdougall
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of SG11201707497UA publication Critical patent/SG11201707497UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201707497UA 2015-03-13 2016-03-14 Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease SG11201707497UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562133128P 2015-03-13 2015-03-13
US201562250921P 2015-11-04 2015-11-04
PCT/US2016/022319 WO2016149191A1 (en) 2015-03-13 2016-03-14 Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Publications (1)

Publication Number Publication Date
SG11201707497UA true SG11201707497UA (en) 2017-10-30

Family

ID=56920255

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201908500U SG10201908500UA (en) 2015-03-13 2016-03-14 Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
SG11201707497UA SG11201707497UA (en) 2015-03-13 2016-03-14 Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201908500U SG10201908500UA (en) 2015-03-13 2016-03-14 Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Country Status (18)

Country Link
US (2) US10912751B2 (en)
EP (1) EP3267989A4 (en)
JP (2) JP6940411B2 (en)
KR (1) KR102370582B1 (en)
CN (2) CN114099496A (en)
AU (2) AU2016233485B2 (en)
BR (1) BR112017019358A2 (en)
CA (1) CA2978204A1 (en)
CL (1) CL2017002299A1 (en)
IL (1) IL254194A0 (en)
MA (1) MA42616A (en)
MX (2) MX2017011499A (en)
PH (1) PH12017501625A1 (en)
RU (2) RU2022102472A (en)
SG (2) SG10201908500UA (en)
UA (1) UA123355C2 (en)
WO (1) WO2016149191A1 (en)
ZA (1) ZA201706919B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123355C2 (en) 2015-03-13 2021-03-24 Есперіон Терапеутікс, Інк. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (en) 2015-03-16 2018-01-23 Esperion Therapeutics Inc FIXED DOSE ASSOCIATIONS INCLUDING ETC1002 AND ONE OR MORE STATINS TO TREAT OR REDUCE A CARDIOVASCULAR RISK
BR112019016307A2 (en) * 2017-02-08 2020-03-31 Esperion Therapeutics, Inc. TRIPLET COMBINATION FORMULATIONS AND METHODS TO TREAT OR REDUCE THE RISK OF CARDIOVASCULAR DISEASE
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
WO2019179494A1 (en) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 Substituted pentadecanedioic acid compound and pharmaceutical composition and use thereof
WO2020046836A1 (en) * 2018-08-27 2020-03-05 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions
CN115429784A (en) 2019-06-21 2022-12-06 艾斯柏伦治疗公司 Process for preparing biparidic acid and compositions thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1304093A (en) 1919-05-20 Camera
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
US3441605A (en) 1965-02-17 1969-04-29 Wallace & Tiernan Inc Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
GB1196594A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Improvements in and relating to the production of Sebacic Acid
GB1196597A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of an Oxido-Cyclodecene
GB1196595A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Lactone
FR1545224A (en) 1966-12-21 1968-11-08 Geigy Ag J R Process for preparing sebacic acid
GB1196598A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Ketosebacic Acid
GB1196596A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a hydroxysebacic acid
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4281200A (en) 1979-08-30 1981-07-28 The Dow Chemical Company Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
JPS5639033A (en) 1979-09-04 1981-04-14 Kao Corp Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (en) 1983-05-30 1987-04-08 Luso Farmaco Inst 3- (3-HYDROXYBUTOXY) -1-BUTANOL AND ITS PREPARATION METHOD
JPS59232811A (en) 1983-06-16 1984-12-27 Sumitomo Chem Co Ltd Preparation of aromatic polyamide-imide resin molding
JPS60136512A (en) 1983-12-26 1985-07-20 Eisai Co Ltd Remedy and preventive for hyperlipemia
DE3423166A1 (en) 1984-06-22 1986-01-02 Epis S.A., Zug ALPHA, OMEGA DICARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4896344A (en) 1984-10-15 1990-01-23 Grady John K X-ray video system
US4634119A (en) 1985-07-11 1987-01-06 Pesthy Paul K Resilient exercise machine with body support platform
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
JP2999579B2 (en) 1990-07-18 2000-01-17 武田薬品工業株式会社 DNA and its uses
US5254589A (en) 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5420339A (en) 1993-11-22 1995-05-30 Warner-Lambert Company Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
JP2937012B2 (en) 1994-04-08 1999-08-23 時久 増田 Method and apparatus for manufacturing rectangular tubular packaging bag
US5504073A (en) 1994-07-01 1996-04-02 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5578639A (en) 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
SE9500778D0 (en) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
JPH11515025A (en) 1995-11-02 1999-12-21 ワーナー−ランバート・コンパニー Methods and pharmaceutical compositions for regulating lipid concentration
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6093744A (en) 1997-04-21 2000-07-25 Warner-Lambert Company N-acyl sulfamic acid esters useful as hypocholesterolemic agents
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CN1160068C (en) 1997-11-25 2004-08-04 沃尼尔·朗伯公司 Inihibition of lipoprotein oxidation
CA2353981C (en) 1998-12-07 2005-04-26 Schering Corporation Process for the synthesis of azetidinones
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
US6410802B1 (en) 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
IL155215A0 (en) 2000-10-11 2003-11-23 Esperion Therapeutics Inc Ether compounds and compositions for cholesterol management and related uses
MXPA03003022A (en) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Sulfide and disulfide compounds and compositions for cholesterol management and related uses.
WO2002030860A2 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
MXPA03003024A (en) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7053046B2 (en) 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
MXPA05007674A (en) 2003-01-23 2005-09-22 Esperion Therapeutics Inc Hydroxyl compounds and compositions for cholesterol management and related uses.
US20050171080A1 (en) 2003-12-23 2005-08-04 Dr. Reddy's Laboratories, Inc. Polymorphs of ezetimibe and process for preparation thereof
US7705177B2 (en) 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
JP4553181B2 (en) 2004-03-25 2010-09-29 株式会社サタケ Pesticide residue analysis method
US7194579B2 (en) 2004-04-26 2007-03-20 Sun Microsystems, Inc. Sparse multi-component files
WO2007058335A1 (en) 2005-11-15 2007-05-24 Takeda Pharmaceutical Company Limited Use of tak-475 together with ezetimibe for treating hyperlipidemia
KR20150090284A (en) 2007-03-24 2015-08-05 젠자임 코포레이션 Administering antisense oligonucleotides complementary to human apolipoprotein b
US8209479B2 (en) 2007-07-18 2012-06-26 Google Inc. Memory circuit system and method
WO2009074286A2 (en) 2007-12-10 2009-06-18 Ratiopharm Gmbh Pharmaceutical formulation comprising ezetimibe
EP2168573A1 (en) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
ATE536172T1 (en) 2009-03-13 2011-12-15 Sanovel Ilac Sanayi Ve Ticaret As EZETIMIBE COMPOSITIONS
AU2011305610A1 (en) 2010-09-20 2013-03-14 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
AR083417A1 (en) 2010-10-14 2013-02-21 Novartis Ag PHARMACEUTICAL COMPOSITIONS CONTAINING AN INHIBITOR DGAT1
AR086675A1 (en) 2011-06-14 2014-01-15 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF INHIBITORS OF DIPEPTIDIL PEPTIDASA-4 WITH SIMVASTATIN
JP6158813B2 (en) 2011-09-16 2017-07-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Method of reducing lipoprotein (a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
AU2013207423B2 (en) 2012-01-06 2017-10-12 Gemphire Therapeutics Inc. Methods of reducing risk of cardiovascular disease
WO2013158810A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release pharmaceutical compositions with abuse deterrent properties
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2931718B1 (en) 2012-12-17 2019-01-16 Merck Sharp & Dohme Corp. Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
UA123355C2 (en) 2015-03-13 2021-03-24 Есперіон Терапеутікс, Інк. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (en) 2015-03-16 2018-01-23 Esperion Therapeutics Inc FIXED DOSE ASSOCIATIONS INCLUDING ETC1002 AND ONE OR MORE STATINS TO TREAT OR REDUCE A CARDIOVASCULAR RISK
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
BR112019016307A2 (en) 2017-02-08 2020-03-31 Esperion Therapeutics, Inc. TRIPLET COMBINATION FORMULATIONS AND METHODS TO TREAT OR REDUCE THE RISK OF CARDIOVASCULAR DISEASE
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
KR20210079275A (en) 2018-08-24 2021-06-29 에스페리온 테라피유틱스 인코포레이티드 How to Reduce the Risk of Diabetes in Patients Being Treated for High Cholesterol-Related Diseases
WO2020046836A1 (en) 2018-08-27 2020-03-05 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions

Also Published As

Publication number Publication date
CL2017002299A1 (en) 2018-03-16
RU2022102472A (en) 2022-03-15
PH12017501625A1 (en) 2018-02-12
RU2766085C2 (en) 2022-02-07
AU2016233485B2 (en) 2021-05-20
JP2018507901A (en) 2018-03-22
US11744816B2 (en) 2023-09-05
US20210361605A1 (en) 2021-11-25
MX2022005469A (en) 2022-06-02
ZA201706919B (en) 2022-03-30
RU2017136180A3 (en) 2019-09-19
CA2978204A1 (en) 2016-09-22
JP7295179B2 (en) 2023-06-20
US20180064671A1 (en) 2018-03-08
AU2021218120A1 (en) 2021-09-09
EP3267989A4 (en) 2018-11-07
RU2017136180A (en) 2019-04-15
BR112017019358A2 (en) 2018-05-08
KR102370582B1 (en) 2022-03-04
KR20180006887A (en) 2018-01-19
CN107530307A (en) 2018-01-02
JP6940411B2 (en) 2021-09-29
UA123355C2 (en) 2021-03-24
SG10201908500UA (en) 2019-11-28
MX2017011499A (en) 2018-03-26
AU2016233485A1 (en) 2017-11-02
IL254194A0 (en) 2017-10-31
US10912751B2 (en) 2021-02-09
WO2016149191A1 (en) 2016-09-22
MA42616A (en) 2021-05-19
EP3267989A1 (en) 2018-01-17
JP2021193105A (en) 2021-12-23
CN114099496A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
HK1258205A1 (en) Compositions and methods for the treatment of hemoglobinopathies
IL277648A (en) Therapeutic microbiota for the treatment and/or prevention of food allergy
IL265590B (en) Keratin treatment formulations and methods
HK1259458A1 (en) Gemcabene combinations for the treatment of cardiovascular disease
HK1258396A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
ZA201706919B (en) Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
IL258854A (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
HK1245643A1 (en) Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk
HK1257853A1 (en) Compositions and methods for the treatment and prevention of radiation dermatitis
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
IL270011B (en) Therapeutic compounds and methods
HK1258999A1 (en) Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver
HK1255695A1 (en) Composition and methods for the treatment of blepharoptosis
GB201511799D0 (en) Composition and methods of treatment
ZA201802201B (en) Novel formulation and treatment methods
IL257689B (en) Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases
IL246608A0 (en) Compositions and methods for treating heart disease
GB201523010D0 (en) The combination of chinese medicine treating menstruation
GB201508518D0 (en) Hair treatment compositions and methods
GB201516437D0 (en) Compositions and methods relating to the treatment of disease
GB201403086D0 (en) Selection of virus and agent useful in the treatment of cancer